View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2053-10-15 |
| Par Value | 2000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 1000.00 |
| Coupon | 5.55 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1000.000 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Gilead Sciences, Inc. corporate note has a 5.55% fixed rate coupon paid on a semi-annual basis. It was issued on September 14, 2023 with an issue size of 1000.00 million USD and matures on October 15, 2053 with a last coupon date of April 15, 2053. |
Gilead Sciences, Inc., founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines primarily in the areas of antiviral therapies, including treatments for HIV, hepatitis B, hepatitis C, and influenza. Key products include the antiviral drugs Biktarvy, Truvada, and Harvoni, which have made significant impacts in their respective therapeutic areas.